These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37807065)

  • 1. Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.
    Dobilas A; Jansåker F; Li X; Sundquist K; Borgfeldt C
    BMC Cancer; 2023 Oct; 23(1):951. PubMed ID: 37807065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
    Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of nonovarian cancer in a nationwide-based study of nearly 5000 women with borderline ovarian tumors in Denmark.
    Hannibal CG; Baandrup L; Hertzum-Larsen R; Vang R; Kurman RJ; Frederiksen K; Kjaer SK
    Int J Cancer; 2023 Apr; 152(7):1370-1377. PubMed ID: 36366853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Guleria S; Jensen A; Kjær SK
    Gynecol Oncol; 2018 Jan; 148(1):86-90. PubMed ID: 29174556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
    Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Borderline Ovarian Tumors Share Familial Risks with Themselves and Invasive Cancers.
    Zheng G; Yu H; Kanerva A; Försti A; Sundquist K; Hemminki K
    Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1358-1363. PubMed ID: 30018148
    [No Abstract]   [Full Text] [Related]  

  • 8. Second neoplasms after invasive and borderline ovarian cancer.
    Levi F; Randimbison L; Blanc-Moya R; La Vecchia C
    Eur J Cancer Prev; 2009 Jun; 18(3):216-9. PubMed ID: 19491608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cancer among patients with atopic dermatitis.
    Hagströmer L; Ye W; Nyrén O; Emtestam L
    Arch Dermatol; 2005 Sep; 141(9):1123-7. PubMed ID: 16172309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.
    Rizzuto I; Behrens RF; Smith LA
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008215. PubMed ID: 31207666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma.
    Hemminki K; Aaltonen L; Li X
    Cancer; 2003 May; 97(10):2432-9. PubMed ID: 12733142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study.
    Lundberg FE; Johansson ALV; Rodriguez-Wallberg K; Gemzell-Danielsson K; Iliadou AN
    Eur J Epidemiol; 2019 Nov; 34(11):1093-1101. PubMed ID: 31377935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007.
    Kalapotharakos G; Högberg T; Bergfeldt K; Borgfeldt C
    Acta Obstet Gynecol Scand; 2016 Apr; 95(4):473-9. PubMed ID: 26714557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormone therapy and cancer risk: An overestimated risk?
    Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
    Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study.
    Bergfeldt K; Einhorn S; Rosendahl I; Hall P
    Acta Oncol; 1995; 34(6):771-7. PubMed ID: 7576744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation.
    Williams CL; Jones ME; Swerdlow AJ; Botting BJ; Davies MC; Jacobs I; Bunch KJ; Murphy MFG; Sutcliffe AG
    BMJ; 2018 Jul; 362():k2644. PubMed ID: 29997145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acromegaly and cancer risk: a cohort study in Sweden and Denmark.
    Baris D; Gridley G; Ron E; Weiderpass E; Mellemkjaer L; Ekbom A; Olsen JH; Baron JA; Fraumeni JF
    Cancer Causes Control; 2002 Jun; 13(5):395-400. PubMed ID: 12146843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
    Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
    Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.